FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
UPI22d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Johnson & Johnson's Spravato ... Advertisement The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the Montgomery-Asberg Depression ...
NBC New York23d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.